Avadel Pharmaceuticals — Q2 2018 Earnings Presentation
24 slides from Avadel Pharmaceuticals's earnings presentation, Aug 7, 2018
Slide 1: Second Quarter 2018 Earnings Conference Call
Second Quarter 2018 Earnings Conference Call August 7, 2018
Slide 2: Safe Harbor
Safe Harbor This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and
Slide 3: 2Q 2018 Call Outline
2Q 2018 Call Outline I. Opening remarks II. REST-ON Phase III trial I. Enrollment II. Protocol amendment III. Initiatives & new sites III. NOCTIVA™ launch update I. Demand, prescribers, and awareness II. Coverage progress III. Life cycle management IV. Financial Results 3
Slide 4: 2Q 2018 Overview
2Q 2018 Overview Akovaz® • Hospital products have Total provided cash to transition Hospital Products company from drug delivery to Bloxiverz® Revenue specialty pharma $29M • Major long-term value opportunities with NOCTIVA Urology Vazculep® and FT 218 (investigational) • 4th hospital product (AV 00
Slide 5: REST-ON Phase III Trial
\Avadel” REST-ON Phase III Trial
Slide 6: REST-ON Status Update
REST-ON Status Update Enrollment Progress Total Needed Enrolled • Majority of patients from US and Canada • Only fully operation in US since 2Q 2017 due to site initiation delays in part from: • DEA licensing procedural change 264 • Delayed IRB approval • Additional sites & enrollment initiatives is
Slide 7: Protocol Change
Protocol Change • Prior to June 2018, patients had to be naïve to sodium oxybate • New protocol admits patients with limited past use of sodium oxybate who meet the following criteria: Dose of sodium Duration on drug At least one year Initial review, via online oxybate never for no more than 2 since
Slide 8: REST-ON Status Update
REST-ON Status Update Majority of patients enrolled to date from US and Canada Only fully operation in US since 2Q 2017 7 new US sites in US & 3 Australian sites to be initiated over next few months 16 total sites to open by Q1 2019 Specific site closures pending 8
Slide 9: REST-ON Status Update
REST-ON Status Update High awareness for FT 218 & REST-ON: over 2,000 online screening questionnaires completed Almost 50% of patients discontinue sodium oxybate within 12 months - recent data suggests ~27% patients non-compliant with 2nd dose1 Qualitative market research shows physician preference
Slide 10: NOCTIVA Launch Update
\yAvadel” NOCTIVA™ Launch Update
Slide 11: NOCTIVA: 2018 Revenue Guidance
NOCTIVA™: 2018 Revenue Guidance Updated full year 2018 revenue guidance: $5 - $10 million Net revenue realized a function of: • Mix of Medicare Part D to commercial insurance plans – no preferred brand Part D coverage to date • Commercial copay assistance for non-preferred brand status plans Over 2,
Slide 12: NOCTIVA: Increasing Awareness
NOCTIVA™: Increasing Awareness 1st >10 % To market in Have nocturia and Less than 10% are Over 60% unaided indication never wake 2 or more diagnosed and brand awareness, before approved times per night to being treated2-8 up from 15%, in 2 urinate1 months promotion 1. Bosch JLH, Weiss JP. The preval
Slide 13: NOCTIVA: Keys to Success
NOCTIVA™: Keys to Success ➢ Increase relevance of nocturia and condition to be treated independently • Up to 9 new publications over coming months to highlight innovation of Noctiva and importance of treating nocturia ➢ Increase trial and experience for physicians and patients • Over 7,000 full-size
Slide 14: NOCTIVA: Life Cycle Management & Market Expansion
NOCTIVA™: Life Cycle Management & Market Expansion • Decision to pursue approval for NOCTIVA in Canada • Initiated formulation and regulatory work to seek approval for primary nocturnal enuresis (PNE) and other new formulation • NOCTIVA peak revenue opportunity $250M-400M peak revenue from $250 - $7
Slide 15: Second Quarter 2018 Financial Results
Second Quarter 2018 Financial Results 15
Slide 16: Non-GAAP Financial Results
Non-GAAP Financial Results Three Months Ended (in $000s, except for per share amounts 06/30/18 03/31/18 06/30/17 Total revenues $ 29,230 $ 33,293 $ 47,411 Cost of products 3,512 6,592 4,561 Research and development expenses 11,890 9,951 6,792 Selling, general and admin expenses 27,843 24,487 12,429
Slide 17: GAAP Financial Results
GAAP Financial Results Three Months Ended (in $000s, except for per share amounts 06/30/18 03/31/18 06/30/17 Total revenues $ 29,230 $ 33,293 $ 46,311 Cost of products 3,512 6,592 4,561 Research and development expenses 11,890 9,951 6,792 Selling, general and admin expenses 27,843 24,487 12,429 Inta
Slide 18: Cash Flow Summary
Cash Flow Summary in $000's Six Months ended June 30, 2018 2017 TOTAL Cash and Marketable Securities Beginning Balance $ 94,075 $ 154,195 Operating cash flows (excl earnouts and tax payments) (24,802) 62,608 Earnout payments (12,731) (19,467) Tax Payments (409) (9,605) Total Operating Cash Flows (37
Slide 19: Updated 2018 Guidance
Guidance Updated Guidance 2018 Guidance Revenue - Total $90M - $105M Revenue - Noctiva $5M - $10M R&D Expense $40M - $50M SG&A Expense $80M - $90M Cash Interest Expense $6M Income Tax Benefit – Non-GAAP 0% - 10% 19
Slide 20: Question & Answer
\Avadel” Question & Answer
Slide 21: Appendix
\Avadel” Appendix
Slide 22: GAAP to Non-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations (in $000s, except for per share amounts) GAAP to Non-GAAP adjustments for the three months ended June 30, 2018 Exclude Include Contingent Equity securities Amortization of related party Contingent Foreign unrealized debt discount payable related party Intangible asse
Slide 23: GAAP to Non-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations (in $000s, except for per share amounts) GAAP to Non-GAAP adjustments for the three months ended March 31, 2018 Exclude Include Contingent Amortization of related party Contingent Foreign Equity Securities debt discount payable related party Intangible asset exchange
Slide 24: GAAP to Non-GAAP Reconciliations
GAAP to NON-GAAP Reconciliations (in $000s, except for per share amounts) GAAP to Non-GAAP adjustments for the three months ended June 30, 2017 Exclude Include Contingent related party Contingent Foreign payable related party Intangible asset exchange (loss) Restructuring License revenue fair value
Avadel Pharmaceuticals — Q2 2018 Earnings Presentation on 6ix